Biological therapy for pediatric malignancy: current perspectives

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Biologicals are tumor-specific agents, with notable successes in targeting genetic translocations like BCR-ABL in chronic myeloid leukemia (CML).
• Pediatric cancers have not yet seen similar dramatic results from targeted genetic therapies due to rarity and ethical considerations.
• Biologicals pose unique challenges in testing and development, often not lending themselves to standard in vitro assays.

Purpose of the Study:

• To review the current landscape and challenges of biological agents in cancer treatment, particularly in pediatric oncology.
• To explore novel therapeutic avenues including targeting the tumor microenvironment and modulating the host immune response.
• To highlight the role of biological agents in supportive care for reducing chemotherapy toxicity and managing infections.

Main Methods:

• Review of existing literature on biological agents in cancer therapy.
• Analysis of successes and limitations of targeted therapies in adult and pediatric cancers.
• Exploration of emerging strategies such as microenvironment targeting and immunotherapy.

Main Results:

• While adult cancers have seen success with targeted biologicals, pediatric oncology lags behind.
• Monoclonal antibodies were early attempts at solid tumor targeting.
• The tumor microenvironment and immune response modulation represent promising new biological approaches.

Conclusions:

• Biological agents are advancing cancer treatment, offering targeted specificity and supportive care benefits.
• Further research is needed to overcome challenges in pediatric cancer targeting and biological agent development.
• Novel approaches targeting the tumor microenvironment and immune system hold significant potential for future therapies.